No profile data available.
Vanda Pharmaceuticals Inc. (VNDA) is a healthcare company in the brain and nerve treatment drugs industry, based in Washington, United States, with about 533 full-time employees.
It reported revenue of $216.11 million for fiscal year 2025, up 8.7% from fiscal year 2024, and net income of -$220.47 million. Its market capitalization was $276.31 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Vanda Pharmaceuticals reported $216.11 million in revenue for fiscal year 2025, up 8.7% from $198.77 million in fiscal year 2024.
$276.31 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Benitec Biopharma Inc. (BNTC), Fulcrum Therapeutics, Inc. (FULC), Larimar Therapeutics, Inc. (LRMR), Inhibikase Therapeutics, Inc. (IKT).